cytotoxic T-lymphocyte antigen-4

cytotoxic T-lymphocyte antigen-4 (CTLA-4),

expressed by activated T cells. When synthesized as a soluble molecule fused to the Fc of IgG, it is used as a biologic therapy in rhematic diseases, because it blocks a costimulatory molecule on B lymphocytes.

Mentioned in ?

CTLA-4

References in periodicals archive ?

According to the company, AGEN1884 is an immune checkpoint modulator (CPM) antibody that binds to cytotoxic T-lymphocyte antigen-4 (CTLA-4).

Promising clinical data from studies employing monoclonal antibodies that bind to checkpoint molecules, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death receptor-1 (PD-1), have generated considerable excitement in the field of cancer immunotherapy, concluded the company.

Agenus' anti-CTLA-4 and anti-GITR Antibodies IND passes US FDA clearance

Cytotoxic T-lymphocyte antigen-4 (CTLA-4): a negative feedback mechanism that limits the body's developing immune response to keep it from becoming overactivated and causing nonspecific damage

Address the nursing challenges associated with treatment for advanced melanoma: as seen in the Clinical Journal of Oncology Nursing and Oncology Nursing Forum